Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Anchor Investment Management LLC

Anchor Investment Management LLC reduced its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,148 shares of the medical equipment provider’s stock after selling 610 shares during the period. Anchor Investment Management LLC’s holdings in Zimmer Biomet were worth $1,311,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in ZBH. American Century Companies Inc. boosted its holdings in shares of Zimmer Biomet by 12.6% during the 2nd quarter. American Century Companies Inc. now owns 6,463,845 shares of the medical equipment provider’s stock worth $701,521,000 after purchasing an additional 722,041 shares during the last quarter. Equity Investment Corp acquired a new position in shares of Zimmer Biomet during the 3rd quarter worth approximately $70,104,000. Hotchkis & Wiley Capital Management LLC boosted its holdings in shares of Zimmer Biomet by 49.1% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider’s stock worth $189,161,000 after purchasing an additional 577,320 shares during the last quarter. Magnetar Financial LLC lifted its holdings in Zimmer Biomet by 58.7% in the second quarter. Magnetar Financial LLC now owns 1,310,265 shares of the medical equipment provider’s stock valued at $142,203,000 after acquiring an additional 484,816 shares during the last quarter. Finally, Van ECK Associates Corp lifted its holdings in Zimmer Biomet by 12.4% in the third quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider’s stock valued at $391,239,000 after acquiring an additional 411,163 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $106.84 on Friday. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. The firm has a fifty day moving average price of $107.59 and a 200 day moving average price of $108.83. The company has a market cap of $21.27 billion, a P/E ratio of 20.31, a PEG ratio of 1.96 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 12 month low of $101.47 and a 12 month high of $133.90.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting analysts’ consensus estimates of $1.74. The firm had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The company’s revenue was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.65 earnings per share. Sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ZBH has been the topic of a number of recent analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a report on Thursday, October 31st. Evercore ISI decreased their price objective on Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a report on Tuesday, October 1st. Raymond James decreased their price objective on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a report on Monday, October 14th. Wolfe Research began coverage on Zimmer Biomet in a research report on Tuesday, September 10th. They issued a “peer perform” rating on the stock. Finally, Royal Bank of Canada boosted their target price on Zimmer Biomet from $120.00 to $125.00 and gave the company an “outperform” rating in a research report on Monday, November 4th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $122.83.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.